In addition, a patient with prostate carcinoma (BRAF V600E mutation by the CLIA, but not Idylla) and colorectal cancer (BRAF V600E mutation by the Idylla, but not CLIA) never received BRAF or MEK inhibitors. Here, MAP2K7 is linked to prostate carcinoma.